

# Resource Summary Report

Generated by [kravitz2](#) on Aug 26, 2026

## BD Biosciences: Accuri C6 Plus Flow Cytometer

RRID:SCR\_019591

Type: Tool

---

### Proper Citation

BD Biosciences: Accuri C6 Plus Flow Cytometer (RRID:SCR\_019591)

---

### Resource Information

**URL:** <https://www.bdbiosciences.com/en-us/products/instruments/flow-cytometers/research-cell-analyzers/bd-accuri-c6-plus>

**Proper Citation:** BD Biosciences: Accuri C6 Plus Flow Cytometer (RRID:SCR\_019591)

**Description:** Compact 11 x 14.75 x 16.5-inch footprint, light weight of 30 lb, and operational simplicity, benchtop flow cytometer is equipped with blue and red laser, two light scatter detectors and four fluorescence detectors with optical filters optimized for detection of many popular fluorochromes, including FITC, PE, PerCP-Cy5.5 and APC. Data are digitally collected over wide dynamic range.

**Synonyms:** BD Accuri C6 Plus

**Resource Type:** instrument resource

**Keywords:** BD Biosciences, Flow Cytometer, Cell Analyzer, Instrument Equipment, USEdit

**Availability:** Commercially available

**Specification URL:** [https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR\\_019591.pdf](https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_019591.pdf)

**Resource Name:** BD Biosciences: Accuri C6 Plus Flow Cytometer

**Resource ID:** SCR\_019591

**Alternate IDs:** Model\_Number\_C6

**Old URLs:** <https://www.bdbiosciences.com/instruments/accuri/>

**Record Creation Time:** 20220129T080345+0000

**Record Last Update:** 20260815T182622+0000

---

## Ratings and Alerts

No rating or validation information has been found for BD Biosciences: Accuri C6 Plus Flow Cytometer.

No alerts have been found for BD Biosciences: Accuri C6 Plus Flow Cytometer.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 22 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Wang J, et al. (2026) Tumor-Resident Streptococcus pneumoniae Promotes Malignant Progression and Pazopanib Resistance in Clear Cell Renal Cell Carcinoma. Cancer research, 86(9), 2237.

Mi Y, et al. (2026) Novel BLT1 inhibitor baeckein E ameliorates LPS-induced acute lung injury through ferroptosis inhibition. Phytomedicine : international journal of phytotherapy and phytopharmacology, 155, 158147.

Martínez-Armenta CA, et al. (2026) Evaluation of the CIB1R peptide derived from the cytoplasmic domain of neprilysin on cell migration in an in vitro model of lung cancer. Frontiers in oncology, 16, 1825515.

Steyn M, et al. (2025) Protocol for simultaneous detection of PRRS virus infection and dying cell populations by a flow cytometry double-staining approach. STAR protocols, 6(1), 103688.

Morán-Vaquero A, et al. (2025) C3G deregulation uncovers a dual role in B-cell lymphoma: tumor suppression and enhanced metastasis via Rap1 and Rac2 signaling. Cell communication and signaling : CCS, 24(1), 11.

Landi D, et al. (2025) A Checkpoint Reversal Receptor Mediates Bipartite Activation and Enhances CAR T-cell Function. Cancer research communications, 5(3), 527.

Mitsuno K, et al. (2025) Selective JAK2 pathway inhibition enhances anti-leukemic functionality in CD19 CAR-T cells. Cancer immunology, immunotherapy : CII, 74(3), 79.

Zhang W, et al. (2025) RACK1 attenuates pancreatic tumorigenesis by suppressing acinar-to-ductal metaplasia through inflammatory signaling modulation. Cellular oncology (Dordrecht, Netherlands).

Berger HR, et al. (2025) Endoglin-Directed CAR T Cells Comprehensively Target Tumors in Advanced Sarcomas. Cancer immunology research, 13(10), 1591.

- Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.
- Qu K, et al. (2025) Enhancement of antitumor immunity by CTLA-4 antisense oligonucleotides with CpG motif in mice. *International immunopharmacology*, 167, 115648.
- Toyokuni E, et al. (2025) Combination therapy of avutometinib and MRTX1133 synergistically suppresses cell growth by inducing apoptosis in KRASG12D-mutated pancreatic cancer. *Molecular cancer therapeutics*.
- Qadri S, et al. (2024) Sex-Dependent Occlusive Cardiovascular Disease Effects of Short-Term Thirdhand Smoke Exposure. *Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco*, 26(9), 1225.
- Boutin L, et al. (2024) Camelid-derived Tcell engagers harnessing human ?? T cells as promising antitumor immunotherapeutic agents. *European journal of immunology*, 54(8), e2350773.
- Wang R, et al. (2024) Kaempferol-3-O-sophoroside (PCS-1) contributes to modulation of depressive-like behaviour in C57BL/6J mice by activating AMPK. *British journal of pharmacology*, 181(8), 1182.
- Sobh A, et al. (2024) NSD2 drives t(4;14) myeloma cell dependence on adenylate kinase 2 by diverting one-carbon metabolism to the epigenome. *Blood*, 144(3), 283.
- Ullah I, et al. (2023) The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. *Cell reports. Medicine*, 4(1), 100893.
- Dong RF, et al. (2023) Discovery of a potent inhibitor of chaperone-mediated autophagy that targets the HSC70-LAMP2A interaction in non-small cell lung cancer cells. *British journal of pharmacology*.
- Zhao Y, et al. (2023) Debugging and consolidating multiple synthetic chromosomes reveals combinatorial genetic interactions. *Cell*, 186(24), 5220.
- Stern LA, et al. (2022) Engineered IL13 variants direct specificity of IL13R $\alpha$ 2-targeted CAR T cell therapy. *Proceedings of the National Academy of Sciences of the United States of America*, 119(33), e2112006119.